(function(){var loadHandler=window['sl_{EC00A760-FAC2-48CD-8603-FA3C7FB92E6B}'];loadHandler&&loadHandler(23, '<div id="spr0_36553f9"><div id="spr1_36553f9" class="kern slide"><img id="img4_36553f9" src="data/img9.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_36553f9" class="kern slide"><img id="img0_36553f9" src="data/img10.png" width="1280" height="719.933" alt=""/><div id="spr3_36553f9" style="left:84.896px;top:40.623px;"><div style="width:0px;"><span id="txt0_36553f9" data-width="1044.421875" style="left:9.6px;top:5.219px;">Site-agnostic development and histology-independent</span></div><div style="width:0px;"><span id="txt1_36553f9" data-width="618.562500" style="left:9.6px;top:57.059px;">tumour agnostic therapies (TAx)</span></div></div><div id="spr4_36553f9" style="left:-0px;top:209.802px;"><img id="img1_36553f9" src="data/img47.png" width="1227" height="82.5" alt="" style="left:0.311px;top:-0.143px;"/></div><div id="spr5_36553f9" style="left:-14.667px;top:229.961px;"><img id="img2_36553f9" src="data/img48.png" width="1224.75" height="465.75" alt="" style="left:-0.117px;top:-0.074px;"/></div><div id="spr6_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><span id="txt2_36553f9" class="nokern relpos" dir="auto" style="left:9.6px;top:22.183px;">•</span> <span id="txt3_36553f9" class="relpos" data-width="91.191406" style="left:26.598px;top:19.366px;">Entrectinib</span></div></div><div id="spr7_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><span id="txt4_36553f9" data-width="1088.125000" style="left:9.6px;top:53.53px;">Entrectinib is active with durable disease control in patients with ROS1 fusion-positive NSCLC, and is well tolerated with a manageable</span></div><div style="width:0px;"><span id="txt5_36553f9" data-width="1077.451172" style="left:9.6px;top:75.899px;">safety profile, making it amenable to long-term dosing in these patients. Data highlight the need to routinely test for ROS1 fusions to</span></div><div style="width:0px;"><span id="txt6_36553f9" data-width="606.718750" style="left:9.6px;top:97.499px;">broaden therapeutic options for patients with ROS1 fusion-positive NSCLC.</span></div></div><div id="spr8_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><a id="hl0_36553f9" href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30690-4/fulltext" title="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30690-4/fulltext" target="_blank" onclick="document.getElementById(\'coreSpr_6623461\').getCore().processTriggerEffect(this);return document.getElementById(\'coreSpr_6623461\').getCore().gotoLink(this);"><span id="txt7_36553f9" data-width="710.878906" style="left:9.6px;top:131.663px;">https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30690-4/fulltext</span></a></div></div><div id="spr9_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><span id="txt8_36553f9" class="nokern relpos" dir="auto" style="left:9.6px;top:169.414px;">•</span> <span id="txt9_36553f9" class="relpos" data-width="106.894531" style="left:26.598px;top:166.597px;">Larotrectinib</span></div></div><div id="spr10_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><span id="txt10_36553f9" data-width="1115.654297" style="left:9.6px;top:201.53px;">Larotrectinib is highly active in advanced lung cancer patients harbouring NTRK gene fusions, including those with CNS metastases, with a</span></div><div style="width:0px;"><span id="txt11_36553f9" data-width="591.601563" style="left:9.6px;top:223.899px;">favourable safety profile. Results support use in in this population group.</span></div></div><div id="spr11_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><a id="hl1_36553f9" href="https://www.onclive.com/view/larotrectinib-is-highly-active-in-patients-with-ntrk-fusion-nsclc" title="https://www.onclive.com/view/larotrectinib-is-highly-active-in-patients-with-ntrk-fusion-nsclc" target="_blank" onclick="document.getElementById(\'coreSpr_6623461\').getCore().processTriggerEffect(this);return document.getElementById(\'coreSpr_6623461\').getCore().gotoLink(this);"><span id="txt12_36553f9" data-width="767.890625" style="left:9.6px;top:258.063px;">https://www.onclive.com/view/larotrectinib-is-highly-active-in-patients-with-ntrk-fusion-nsclc</span></a></div></div><div id="spr12_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><span id="txt13_36553f9" class="nokern relpos" dir="auto" style="left:9.6px;top:295.814px;">•</span> <span id="txt14_36553f9" class="relpos" data-width="130.957031" style="left:26.598px;top:292.997px;">Pembrolizumab</span></div></div><div id="spr13_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><span id="txt15_36553f9" class="relpos" data-width="314.658203" style="left:9.6px;top:327.93px;">E.g. NSCLC with a PD-L1 TPS ≥50% and </span> <span id="txt16_36553f9" class="relpos" data-width="49.098442" style="left:9.593px;top:327.93px;">EGFR</span> <span id="txt17_36553f9" class="relpos" style="left:9.587px;top:327.93px;">/</span> <span id="txt18_36553f9" class="relpos" data-width="41.559380" style="left:9.58px;top:327.93px;">ALK </span> <span id="txt19_36553f9" class="relpos" data-width="699.931641" style="left:9.573px;top:327.93px;">negative status; agency divergence, e.g., FDA seems to be more flexible, as the agency</span></div><div style="width:0px;"><span id="txt20_36553f9" data-width="873.427734" style="left:9.6px;top:350.299px;">approved pembrolizumab in the MSI-H/dMMR-indication despite including the CRC MSI-H/dMMR tumours.</span></div></div><div id="spr14_36553f9" style="left:83.324px;top:243.908px;"><div style="width:0px;"><a id="hl2_36553f9" href="http://atm.amegroups.com/article/view/27166" title="http://atm.amegroups.com/article/view/27166" target="_blank" onclick="document.getElementById(\'coreSpr_6623461\').getCore().processTriggerEffect(this);return document.getElementById(\'coreSpr_6623461\').getCore().gotoLink(this);"><span id="txt21_36553f9" data-width="386.396484" style="left:9.6px;top:384.463px;">http://atm.amegroups.com/article/view/27166</span></a></div></div><div id="spr15_36553f9" style="left:101.25px;top:4.5px;"><img id="img3_36553f9" src="data/img49.png" width="1077.75" height="730.5" alt=""/></div><div id="spr16_36553f9" style="left:-7.707px;top:301.63px;"><div style="width:0px;"><span id="txt22_36553f9" data-width="1068.707031" style="left:34.119px;top:242.745px;">The assay/CDx defines the indication</span></div><div style="width:0px;"><span id="txt23_36553f9" data-width="1071.050781" style="left:33.119px;top:322.745px;">(disease) and the population to treat…</span></div></div></div></div>', '{"s":[]}');})();